Pseudomonas aeruginosa Pneumonia in Nonsevere Community-Acquired Pneumonia with Recent Hospitalisation and Parenteral Antibiotic Exposure

This protocol applies to adults admitted to hospital with nonsevere community-acquired pneumonia (CAP) who carry locally validated risk factors for Pseudomonas aeruginosa — specifically, hospitalisation and parenteral antibiotic receipt within the preceding 90 days — but have no prior respiratory isolation of P. aeruginosa.

Clinical scenario: Nonsevere CAP managed in the inpatient setting. The defining risk signal is recent hospitalisation and receipt of parenteral antibiotics in the last 90 days, combined with locally validated risk factors for P. aeruginosa. No previous respiratory culture has grown P. aeruginosa.

Empiric coverage for P. aeruginosa should be considered only when locally validated risk factors are present; even then, the threshold for adding antipseudomonal agents is culture confirmation, not empiric reflex.

Treatment approach (partial): Management is built on the standard nonsevere inpatient CAP regimen — a beta-lactam plus macrolide combination, or a respiratory fluoroquinolone as monotherapy. Cultures are obtained at the outset; empiric antipseudomonal coverage is withheld unless culture results confirm P. aeruginosa. The full regimen, sequencing, and duration are in the complete protocol.

Treatment goal: Achievement of clinical stability within 5 days — resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation. Failure to reach stability by day 5 is associated with higher mortality and worse outcomes.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1164/rccm.201908-1581ST

The major additional risk factors for MRSA and P. aeruginosa identified in the literature are hospitalization and parenteral antibiotic exposure in the last 90 days.

We recommend clinicians only cover empirically for MRSA or P. aeruginosa in adults with CAP if locally validated risk factors for either pathogen are present.

Obtain cultures but initiate coverage for P. aeruginosa only if culture results are positive.

combination therapy with a b-lactam (ampicillin-sulbactam, cefotaxime, ceftriaxone, or ceftaroline) and a macrolide (azithromycin or clarithromycin) (strong recommendation, high quality of evidence), or monotherapy with a respiratory fluoroquinolone (levofloxacin, moxifloxacin) (strong recommendation, high quality of evidence).

We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).

Failure to achieve clinical stability within 5 days is associated with higher mortality and worse clinical outcomes.

View source ↗